Literature DB >> 15145238

Hyperthyroidism: advantages and disadvantages of medical therapy.

Elizabeth N Pearce1, Lewis E Braverman.   

Abstract

The most common causes of hyperthyroidism are Graves' disease, toxic nodular goiter, and iodine-induced hyperthyroidism. Hyperthyroidism can be treated medically with antithyroid drugs or radioactive iodine, or surgically. Multiple clinical factors must be weighed when choosing a treatment modality. All of the available forms of therapy have advantages and disadvantages, and treatment choices must be individualized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145238     DOI: 10.1016/j.suc.2004.01.007

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  4 in total

1.  Long-term immunological study in Graves' disease treated with thyroid arterial embolization.

Authors:  Wei Zhao; Bu-Lang Gao; Cang-Zheng Jin; Gen-Fa Yi; Hui-Ying Yang; Hong Li; Dian-Ping Song; Ji-Hong Hu; Yong-Neng Jiang
Journal:  J Clin Immunol       Date:  2008-07-17       Impact factor: 8.317

2.  Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country.

Authors:  P V Pradeep; Amit Agarwal; Mukta Baxi; Gaurav Agarwal; Sushil Kumar Gupta; S K Mishra
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

3.  Redistribution of body composition in patients with Graves' disease after iodine-131 treatment.

Authors:  L-J Xie; H-J Zhou; J-F Li; F Zhang; F-W Zeng; L-P Qin; Y Chen; H-J Yuan; M-H Cheng
Journal:  Eur J Clin Nutr       Date:  2014-10-29       Impact factor: 4.016

4.  Effectiveness of Fixed Dose Radioactive Iodine (RAI) for the Treatment of Hyperthyroidism: Experience of a Teaching Hospital in South West Nigeria.

Authors:  John Enyi Ejeh M; Karounwi Omotayo Ogunjobi; John Enyi Ejeh; Kayode Solomon Adedapo; Joshua F Eniojukan
Journal:  Mol Imaging Radionucl Ther       Date:  2013-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.